Share Price and Basic Stock Data
Last Updated: December 23, 2025, 10:58 am
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
MPS Pharmaa Ltd, operating in the pharmaceuticals sector, reported a current price of ₹1.85 and a market capitalization of ₹3.54 Cr. The company’s journey has been marked by a significant decline in revenue, with sales consistently reported at ₹0.00 from FY 2023 through to FY 2025. This trend reflects a challenging operational environment, as the company faced a steep drop in sales from ₹30.27 Cr in FY 2014 to the current state. The lack of revenue generation over the past three years raises concerns about the company’s market positioning and operational strategy. In contrast, expenses have fluctuated slightly, reaching ₹0.95 Cr in FY 2023 and declining marginally to ₹0.77 Cr in FY 2025. This persistent absence of revenue, coupled with ongoing operational expenses, highlights a critical challenge for MPS Pharmaa Ltd as it navigates through a competitive landscape that demands both innovation and effective market engagement.
Profitability and Efficiency Metrics
The profitability metrics of MPS Pharmaa Ltd illustrate a concerning trend, with the company consistently reporting negative operating profits. The operating profit stood at -₹0.95 Cr in FY 2023 and is projected to remain negative at -₹0.77 Cr for FY 2025. The operating profit margin (OPM) remains unreported, indicative of the ongoing operational challenges faced by the firm. Furthermore, the net profit for FY 2023 was recorded at -₹1.05 Cr, with a slight improvement to -₹0.90 Cr in FY 2025. The company’s return on equity (ROE) is notably high at 59.0%, but this figure does not reflect effective utilization of capital, given the negative net profits. The interest coverage ratio (ICR) is alarmingly low at -1438.08x, suggesting that MPS Pharmaa Ltd is struggling to meet its interest obligations, exacerbating its financial strain and raising red flags for potential investors.
Balance Sheet Strength and Financial Ratios
MPS Pharmaa Ltd’s balance sheet reveals significant vulnerabilities, particularly in its reserves and borrowings. The company reported reserves of -₹18.47 Cr, indicating a substantial deficit that has worsened from -₹15.29 Cr in FY 2022. Total borrowings increased slightly to ₹7.51 Cr, which raises concerns regarding the sustainability of its capital structure. The debt-to-equity ratio stands at a high 6.90, reflecting a heavy reliance on debt financing. The quick ratio is reported at 0.19, which is below the industry average, suggesting that the company may struggle to meet its short-term liabilities. Additionally, the book value per share has declined from ₹2.00 in FY 2022 to ₹0.56 in FY 2025, indicating a deterioration of shareholder value. These financial ratios signal a precarious financial position, heightening the risk of insolvency if operational challenges persist.
Shareholding Pattern and Investor Confidence
The shareholding pattern of MPS Pharmaa Ltd shows a stable yet concerning distribution of ownership. Promoters hold 35.89% of the shares, while the public holds 63.52%, with institutional investors (DIIs) representing only 0.58%. The total number of shareholders decreased from 4,512 in December 2022 to 4,433 by September 2025, suggesting a gradual decline in investor confidence. The absence of Foreign Institutional Investors (FIIs) further reflects the challenges in attracting external investment. The minimal presence of DIIs until December 2024, followed by a slight increase, indicates cautious interest from institutional players. This pattern may suggest that investors are wary of the company’s financial health and operational performance, which could hinder MPS Pharmaa Ltd’s ability to raise capital for potential growth initiatives in the future.
Outlook, Risks, and Final Insight
The outlook for MPS Pharmaa Ltd remains precarious, with several risks overshadowing potential recovery. The continuing absence of revenue generation poses a significant threat to the company’s viability, alongside the high debt levels that could lead to liquidity issues. Additionally, the declining equity value and negative profit margins highlight the urgent need for a strategic overhaul to regain market confidence. However, the high ROE suggests that if the company can stabilize its operations and return to profitability, it may attract renewed investor interest. MPS Pharmaa Ltd must navigate these challenges by possibly restructuring its business model and enhancing operational efficiencies. Should the company manage to reverse its revenue decline and improve its financial ratios, it may find a path to recovery. Conversely, failure to address these issues could lead to further erosion of shareholder value and operational viability.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 138 Cr. | 110 | 231/84.3 | 30.5 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.54 Cr. | 1.85 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,446 Cr. | 408 | 479/192 | 92.1 | 24.3 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.2 Cr. | 47.5 | 88.6/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 49.8 Cr. | 34.0 | 34.7/17.0 | 119 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,302.64 Cr | 1,155.94 | 53.32 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses | 0.17 | 0.24 | 0.23 | 0.31 | 0.19 | 0.21 | 0.18 | 0.21 | 0.19 | 0.19 | 0.18 | 0.19 | 0.19 |
| Operating Profit | -0.17 | -0.24 | -0.23 | -0.31 | -0.19 | -0.21 | -0.18 | -0.21 | -0.19 | -0.19 | -0.18 | -0.19 | -0.19 |
| OPM % | |||||||||||||
| Other Income | 0.00 | 0.00 | 0.00 | 0.02 | 0.03 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
| Profit before tax | -0.21 | -0.28 | -0.27 | -0.33 | -0.20 | -0.19 | -0.22 | -0.25 | -0.23 | -0.23 | -0.18 | -0.23 | -0.23 |
| Tax % | 0.00% | 0.00% | 0.00% | -3.03% | -5.00% | -5.26% | -4.55% | 0.00% | -4.35% | -4.35% | 0.00% | 21.74% | -4.35% |
| Net Profit | -0.20 | -0.27 | -0.26 | -0.32 | -0.19 | -0.18 | -0.21 | -0.24 | -0.22 | -0.22 | -0.17 | -0.28 | -0.22 |
| EPS in Rs | -0.10 | -0.14 | -0.14 | -0.17 | -0.10 | -0.09 | -0.11 | -0.13 | -0.12 | -0.12 | -0.09 | -0.15 | -0.12 |
Last Updated: August 19, 2025, 1:05 pm
Below is a detailed analysis of the quarterly data for MPS Pharmaa Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Expenses, as of Jun 2025, the value is 0.19 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.19 Cr..
- For Operating Profit, as of Jun 2025, the value is -0.19 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded -0.19 Cr..
- For OPM %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 0.04 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.04 Cr..
- For Profit before tax, as of Jun 2025, the value is -0.23 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded -0.23 Cr..
- For Tax %, as of Jun 2025, the value is -4.35%. The value appears to be improving (decreasing) as expected. It has decreased from 21.74% (Mar 2025) to -4.35%, marking a decrease of 26.09%.
- For Net Profit, as of Jun 2025, the value is -0.22 Cr.. The value appears strong and on an upward trend. It has increased from -0.28 Cr. (Mar 2025) to -0.22 Cr., marking an increase of 0.06 Cr..
- For EPS in Rs, as of Jun 2025, the value is -0.12. The value appears strong and on an upward trend. It has increased from -0.15 (Mar 2025) to -0.12, marking an increase of 0.03.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:29 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 30.27 | 12.24 | 1.35 | 2.84 | 4.09 | 0.83 | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses | 27.43 | 11.43 | 1.84 | 9.72 | 4.62 | 1.56 | 0.67 | 4.14 | 0.71 | 0.95 | 0.80 | 0.77 | 0.75 |
| Operating Profit | 2.84 | 0.81 | -0.49 | -6.88 | -0.53 | -0.73 | -0.67 | -4.14 | -0.68 | -0.95 | -0.80 | -0.77 | -0.75 |
| OPM % | 9.38% | 6.62% | -36.30% | -242.25% | -12.96% | -87.95% | -2,266.67% | ||||||
| Other Income | 0.01 | 0.00 | 0.00 | 0.03 | 0.06 | 0.02 | 0.01 | 0.20 | 0.26 | 0.02 | 0.09 | 0.05 | 0.04 |
| Interest | 1.20 | 1.08 | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.68 | 0.65 | 0.62 | 0.59 | 0.59 | 0.59 | 0.57 | 0.56 | 0.51 | 0.15 | 0.15 | 0.15 | 0.16 |
| Profit before tax | 0.97 | -0.92 | -1.19 | -7.44 | -1.06 | -1.30 | -1.23 | -4.50 | -0.93 | -1.08 | -0.86 | -0.87 | -0.87 |
| Tax % | 50.52% | -26.09% | -0.84% | -0.81% | -17.92% | -3.85% | -5.69% | -1.78% | -84.95% | -1.85% | -2.33% | 3.45% | |
| Net Profit | 0.46 | -0.68 | -1.19 | -7.39 | -0.87 | -1.25 | -1.17 | -4.42 | -0.14 | -1.05 | -0.83 | -0.90 | -0.89 |
| EPS in Rs | 0.31 | -0.45 | -0.62 | -3.87 | -0.46 | -0.65 | -0.61 | -2.31 | -0.07 | -0.55 | -0.43 | -0.47 | -0.48 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -247.83% | -75.00% | -521.01% | 88.23% | -43.68% | 6.40% | -277.78% | 96.83% | -650.00% | 20.95% | -8.43% |
| Change in YoY Net Profit Growth (%) | 0.00% | 172.83% | -446.01% | 609.24% | -131.91% | 50.08% | -284.18% | 374.61% | -746.83% | 670.95% | -29.39% |
MPS Pharmaa Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -4% |
| 5 Years: | 4% |
| 3 Years: | % |
| TTM: | -5% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -12% |
| 5 Years: | % |
| 3 Years: | 5% |
| 1 Year: | -47% |
| Return on Equity | |
|---|---|
| 10 Years: | -24% |
| 5 Years: | -44% |
| 3 Years: | -39% |
| Last Year: | -59% |
Last Updated: September 5, 2025, 3:51 pm
Balance Sheet
Last Updated: December 4, 2025, 3:07 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 15.03 | 15.03 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 |
| Reserves | 5.05 | 4.17 | -0.13 | -7.50 | -8.35 | -9.58 | -10.75 | -15.16 | -15.29 | -16.32 | -17.14 | -18.03 | -18.47 |
| Borrowings | 8.22 | 7.78 | 6.65 | 2.90 | 2.90 | 2.51 | 2.53 | 5.68 | 5.81 | 6.77 | 7.27 | 7.46 | 7.51 |
| Other Liabilities | 6.52 | 5.38 | 2.94 | 6.41 | 5.49 | 5.52 | 5.52 | 1.67 | 0.53 | 0.63 | 0.70 | 0.80 | 0.84 |
| Total Liabilities | 34.82 | 32.36 | 28.57 | 20.92 | 19.15 | 17.56 | 16.41 | 11.30 | 10.16 | 10.19 | 9.94 | 9.34 | 8.99 |
| Fixed Assets | 15.18 | 8.21 | 7.64 | 7.06 | 6.47 | 5.88 | 5.26 | 4.68 | 4.17 | 4.14 | 4.01 | 3.83 | 3.74 |
| CWIP | 0.00 | 6.15 | 6.15 | 5.51 | 5.21 | 5.43 | 5.02 | 3.90 | 3.42 | 3.40 | 3.26 | 2.91 | 2.65 |
| Investments | 0.92 | 0.92 | 0.92 | 0.92 | 0.92 | 0.92 | 0.92 | 0.54 | 0.54 | 0.54 | 0.54 | 0.54 | 0.54 |
| Other Assets | 18.72 | 17.08 | 13.86 | 7.43 | 6.55 | 5.33 | 5.21 | 2.18 | 2.03 | 2.11 | 2.13 | 2.06 | 2.06 |
| Total Assets | 34.82 | 32.36 | 28.57 | 20.92 | 19.15 | 17.56 | 16.41 | 11.30 | 10.16 | 10.19 | 9.94 | 9.34 | 8.99 |
Below is a detailed analysis of the balance sheet data for MPS Pharmaa Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 19.11 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 19.11 Cr..
- For Reserves, as of Sep 2025, the value is -18.47 Cr.. The value appears to be worsening (becoming more negative). It has deteriorated from -18.03 Cr. (Mar 2025) to -18.47 Cr., marking a decline of 0.44 Cr..
- For Borrowings, as of Sep 2025, the value is 7.51 Cr.. The value appears to be increasing, which may not be favorable. However, Reserves are negative, which is a major warning sign. It has increased from 7.46 Cr. (Mar 2025) to 7.51 Cr., marking an increase of 0.05 Cr..
- For Other Liabilities, as of Sep 2025, the value is 0.84 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.80 Cr. (Mar 2025) to 0.84 Cr., marking an increase of 0.04 Cr..
- For Total Liabilities, as of Sep 2025, the value is 8.99 Cr.. The value appears to be improving (decreasing). It has decreased from 9.34 Cr. (Mar 2025) to 8.99 Cr., marking a decrease of 0.35 Cr..
- For Fixed Assets, as of Sep 2025, the value is 3.74 Cr.. The value appears to be declining and may need further review. It has decreased from 3.83 Cr. (Mar 2025) to 3.74 Cr., marking a decrease of 0.09 Cr..
- For CWIP, as of Sep 2025, the value is 2.65 Cr.. The value appears to be declining and may need further review. It has decreased from 2.91 Cr. (Mar 2025) to 2.65 Cr., marking a decrease of 0.26 Cr..
- For Investments, as of Sep 2025, the value is 0.54 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.54 Cr..
- For Other Assets, as of Sep 2025, the value is 2.06 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 2.06 Cr..
- For Total Assets, as of Sep 2025, the value is 8.99 Cr.. The value appears to be declining and may need further review. It has decreased from 9.34 Cr. (Mar 2025) to 8.99 Cr., marking a decrease of 0.35 Cr..
However, the Borrowings (7.51 Cr.) are higher than the Reserves (-18.47 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -5.38 | -6.97 | -7.14 | -9.78 | -3.43 | -3.24 | -3.20 | -9.82 | -6.49 | -7.72 | -8.07 | -8.23 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 104.30 | 229.02 | 1,154.48 | 532.08 | 344.47 | 1,147.77 | 365.00 | |||||
| Inventory Days | 94.81 | 274.40 | 6,543.93 | 50.05 | 58.94 | 253.72 | 4,015.00 | 4,562.50 | ||||
| Days Payable | 62.46 | 123.03 | 556.19 | 15.95 | 14.48 | 71.22 | 876.00 | 1,825.00 | ||||
| Cash Conversion Cycle | 136.65 | 380.39 | 7,142.22 | 566.19 | 388.94 | 1,330.27 | 3,504.00 | |||||
| Working Capital Days | 99.72 | 208.74 | 1,724.96 | -115.67 | -87.46 | -848.73 | -49,396.67 | |||||
| ROCE % | 8.18% | 0.58% | -4.22% | -37.07% | -7.53% | -10.12% | -10.73% | -45.61% | -9.66% | -11.26% | -9.15% | -9.79% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -0.47 | -0.43 | -0.55 | -0.07 | -2.31 |
| Diluted EPS (Rs.) | -0.47 | -0.43 | -0.55 | -0.07 | -2.31 |
| Cash EPS (Rs.) | -0.39 | -0.35 | -0.47 | 0.19 | -2.02 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 0.56 | 1.03 | 1.46 | 2.00 | 2.07 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 0.56 | 1.03 | 1.46 | 2.00 | 2.07 |
| Revenue From Operations / Share (Rs.) | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| PBDIT / Share (Rs.) | -0.37 | -0.36 | -0.48 | -0.21 | -2.06 |
| PBIT / Share (Rs.) | -0.45 | -0.44 | -0.56 | -0.48 | -2.35 |
| PBT / Share (Rs.) | -0.45 | -0.44 | -0.56 | -0.48 | -2.35 |
| Net Profit / Share (Rs.) | -0.46 | -0.43 | -0.54 | -0.07 | -2.31 |
| PBDIT Margin (%) | 0.00 | 0.00 | 0.00 | -1290.32 | 0.00 |
| PBIT Margin (%) | 0.00 | 0.00 | 0.00 | -2876.76 | 0.00 |
| PBT Margin (%) | 0.00 | 0.00 | 0.00 | -2880.22 | 0.00 |
| Net Profit Margin (%) | 0.00 | 0.00 | 0.00 | -437.31 | 0.00 |
| Return on Networth / Equity (%) | -83.08 | -42.21 | -37.63 | -3.70 | -111.78 |
| Return on Capital Employeed (%) | -68.24 | -38.85 | -35.47 | -22.83 | -96.84 |
| Return On Assets (%) | -9.62 | -8.36 | -10.31 | -1.39 | -39.07 |
| Total Debt / Equity (X) | 6.90 | 3.69 | 2.42 | 1.52 | 0.48 |
| Current Ratio (X) | 0.25 | 0.27 | 0.29 | 0.33 | 0.32 |
| Quick Ratio (X) | 0.19 | 0.20 | 0.22 | 0.24 | 0.24 |
| Inventory Turnover Ratio (X) | 0.00 | 0.00 | 0.08 | 0.03 | 0.00 |
| Interest Coverage Ratio (X) | -1438.08 | -563.32 | -1722.46 | -373.22 | -7579.04 |
| Interest Coverage Ratio (Post Tax) (X) | -1800.93 | -662.72 | -1955.76 | -125.49 | -8500.46 |
| Enterprise Value (Cr.) | 13.53 | 13.40 | 10.77 | 8.45 | 3.35 |
| EV / Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 261.01 | 0.00 |
| EV / EBITDA (X) | -18.88 | -19.00 | -11.65 | -20.23 | -0.85 |
| MarketCap / Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 82.05 | 0.00 |
| Price / BV (X) | 5.63 | 3.12 | 1.44 | 0.69 | 0.36 |
| Price / Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 86.88 | 0.00 |
| EarningsYield | -0.14 | -0.13 | -0.26 | -0.05 | -3.08 |
After reviewing the key financial ratios for MPS Pharmaa Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -0.47. This value is below the healthy minimum of 5. It has decreased from -0.43 (Mar 24) to -0.47, marking a decrease of 0.04.
- For Diluted EPS (Rs.), as of Mar 25, the value is -0.47. This value is below the healthy minimum of 5. It has decreased from -0.43 (Mar 24) to -0.47, marking a decrease of 0.04.
- For Cash EPS (Rs.), as of Mar 25, the value is -0.39. This value is below the healthy minimum of 3. It has decreased from -0.35 (Mar 24) to -0.39, marking a decrease of 0.04.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 0.56. It has decreased from 1.03 (Mar 24) to 0.56, marking a decrease of 0.47.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 0.56. It has decreased from 1.03 (Mar 24) to 0.56, marking a decrease of 0.47.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.00. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -0.37. This value is below the healthy minimum of 2. It has decreased from -0.36 (Mar 24) to -0.37, marking a decrease of 0.01.
- For PBIT / Share (Rs.), as of Mar 25, the value is -0.45. This value is below the healthy minimum of 0. It has decreased from -0.44 (Mar 24) to -0.45, marking a decrease of 0.01.
- For PBT / Share (Rs.), as of Mar 25, the value is -0.45. This value is below the healthy minimum of 0. It has decreased from -0.44 (Mar 24) to -0.45, marking a decrease of 0.01.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -0.46. This value is below the healthy minimum of 2. It has decreased from -0.43 (Mar 24) to -0.46, marking a decrease of 0.03.
- For PBDIT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBIT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Net Profit Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Return on Networth / Equity (%), as of Mar 25, the value is -83.08. This value is below the healthy minimum of 15. It has decreased from -42.21 (Mar 24) to -83.08, marking a decrease of 40.87.
- For Return on Capital Employeed (%), as of Mar 25, the value is -68.24. This value is below the healthy minimum of 10. It has decreased from -38.85 (Mar 24) to -68.24, marking a decrease of 29.39.
- For Return On Assets (%), as of Mar 25, the value is -9.62. This value is below the healthy minimum of 5. It has decreased from -8.36 (Mar 24) to -9.62, marking a decrease of 1.26.
- For Total Debt / Equity (X), as of Mar 25, the value is 6.90. This value exceeds the healthy maximum of 1. It has increased from 3.69 (Mar 24) to 6.90, marking an increase of 3.21.
- For Current Ratio (X), as of Mar 25, the value is 0.25. This value is below the healthy minimum of 1.5. It has decreased from 0.27 (Mar 24) to 0.25, marking a decrease of 0.02.
- For Quick Ratio (X), as of Mar 25, the value is 0.19. This value is below the healthy minimum of 1. It has decreased from 0.20 (Mar 24) to 0.19, marking a decrease of 0.01.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 4. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -1,438.08. This value is below the healthy minimum of 3. It has decreased from -563.32 (Mar 24) to -1,438.08, marking a decrease of 874.76.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -1,800.93. This value is below the healthy minimum of 3. It has decreased from -662.72 (Mar 24) to -1,800.93, marking a decrease of 1,138.21.
- For Enterprise Value (Cr.), as of Mar 25, the value is 13.53. It has increased from 13.40 (Mar 24) to 13.53, marking an increase of 0.13.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For EV / EBITDA (X), as of Mar 25, the value is -18.88. This value is below the healthy minimum of 5. It has increased from -19.00 (Mar 24) to -18.88, marking an increase of 0.12.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is 5.63. This value exceeds the healthy maximum of 3. It has increased from 3.12 (Mar 24) to 5.63, marking an increase of 2.51.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For EarningsYield, as of Mar 25, the value is -0.14. This value is below the healthy minimum of 5. It has decreased from -0.13 (Mar 24) to -0.14, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in MPS Pharmaa Ltd:
- Net Profit Margin: 0%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -68.24% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -83.08% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -1800.93
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.19
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 53.32)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 6.9
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 138, Roz-Ka-Meo Industrial Area, Sohna, Mewat Dist. Haryana 122103 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Peeyush Kumar Aggarwal | Managing Director |
| Mr. Ram Niwas Sharma | Non Independent Director |
| Ms. Madhu Sharma | Independent Director |
| Mr. Ajay Sharma | Independent Director |
FAQ
What is the intrinsic value of MPS Pharmaa Ltd?
MPS Pharmaa Ltd's intrinsic value (as of 23 December 2025) is 2.38 which is 28.65% higher the current market price of 1.85, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 3.54 Cr. market cap, FY2025-2026 high/low of 4.29/1.76, reserves of ₹-18.47 Cr, and liabilities of 8.99 Cr.
What is the Market Cap of MPS Pharmaa Ltd?
The Market Cap of MPS Pharmaa Ltd is 3.54 Cr..
What is the current Stock Price of MPS Pharmaa Ltd as on 23 December 2025?
The current stock price of MPS Pharmaa Ltd as on 23 December 2025 is 1.85.
What is the High / Low of MPS Pharmaa Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of MPS Pharmaa Ltd stocks is 4.29/1.76.
What is the Stock P/E of MPS Pharmaa Ltd?
The Stock P/E of MPS Pharmaa Ltd is .
What is the Book Value of MPS Pharmaa Ltd?
The Book Value of MPS Pharmaa Ltd is 0.33.
What is the Dividend Yield of MPS Pharmaa Ltd?
The Dividend Yield of MPS Pharmaa Ltd is 0.00 %.
What is the ROCE of MPS Pharmaa Ltd?
The ROCE of MPS Pharmaa Ltd is 9.79 %.
What is the ROE of MPS Pharmaa Ltd?
The ROE of MPS Pharmaa Ltd is 59.0 %.
What is the Face Value of MPS Pharmaa Ltd?
The Face Value of MPS Pharmaa Ltd is 10.0.